Mesothelioma Alternative Cancer Treatment

The clinic has treated many peritoneal mesotheliotics who have achieved "remarkable" results.

# A 64 year old gentleman from Buffalo, New York was diagnosed with pleural malignant mesothelioma in early 1998. He underwent the extra-pleural pneumonectomy by Dr. Sugarbaker, followed by three (3) chemotherapy and fifteen (15) radiation treatments in July of 1998. In September, doctors discovered the mesothelioma had spread to his healthy lung. He was given two (2) months to live. He learned of the IAT clinic from his neighbor and traveled to the Bahamas in December. "I should be dead! But here I am! I feel good and I plan on feeling good for a long time."

# A 77 year old gentleman, also from Buffalo, was diagnosed with pleural malignant mesothelioma in September of 1997. He was offered no treatment and given radiation only to the biopsy wound. His family researched the Internet and local libraries in search of alternative treatments. They discovered the IAT clinic while reading about alternative therapies in a book. He traveled to the Bahamas in September of 1998. "I had to quit working because of the mesothelioma. All my life I got up in the morning and went to work." After going to the IAT clinic, he no longer gets tired "just sitting around." He is able to walk his dog, pull weeds in his yard and, as he puts it -- he has been blessed with the privilege of living.

# Cori Harth was first diagnosed with malignant mesothelioma in 1997 at the age of 49. She is continuing to live a strong and active life. "Having been told I probably would not make it to my 50th birthday, and having celebrated my 51st in the Bahamas doing fantastic, I have ample reason to be very thankful. The mesothelioma is no doubt still "there", but between the laetrile and IAT and stem cell, plus continuing my usual juicing, vitamins and minerals, regular exercise, as well as a good attitude, faith and prayer, my immune system is giving the tumor one heck of a run for its money!!!! All I can say is that it is not anecdotal - they treat many different types of cancers there, and believe me, all you would have to do is spend some hours in the clinic talking to patients from all walks of life. And Dr. Clement is totally open to having anyone talk to the patients, and most patients are happy to do so."

# Two men, ages 45 and 38 respectively, who suffered from peritoneal mesothelioma. Both were diagnosed in 1980. The 45 year old underwent conventional chemotherapy (cytoxan, adriamyein, etc.) prior to arriving at the IAT Clinic. The 38 year old had several of the tumors surgically removed. Both started receiving sera treatment in 1980. As of 1988, both reportedly "were in good health." The brochure is undated.

# A 79 year old liver cancer patient from Minnesota who was diagnosed over one year ago. He joked: "I look pretty good for being dead. My doctors gave me six weeks to live. I've been to more places and seen more things than most people, but I was not ready to give up." This patient learned of the clinic from a friend of his ex-wife.

# A 50 year old breast cancer patient from the East Coast. She was diagnosed two years ago. Her doctors gave her no hope for a cure. She learned of the IAT clinic through her veterinarian. We met a 65 year old prostate cancer patient from Colorado who diagnosed in 1990. His urologist told him of the clinic. He is doing very well.

# An 80 year old breast cancer patient from New York. She was diagnosed five years ago and underwent several chemotherapy treatments. Her doctors told her she was to begin radiation treatments as soon as she "got her health back." She did not wait and traveled to the clinic. Now, she is "too busy with my life to find time to play golf, which I love!"

# A 50 year old breast cancer patient from Huntsville, Alabama. She was first diagnosed in 1981 and was told of the clinic by a friend who was being treated for brain cancer. She stopped taking the treatments in 1991. In 1994, she was diagnosed with liver cancer and offered the same conventional treatment as was offered by her doctors in 1981. She went back to the clinic and resumed taking the sera. Today, she is active and leading a "normal" life.

# A 60 year old leukemia patient from New York. She was diagnosed in the early 1970's. In fact, she was the third patient ever treated with the sera by Dr. Burton.

# A doctor from Scotland who is in complete remission after being diagnosed fifteen (15) years ago. A doctor from St. Louis, Missouri was diagnosed with colon cancer eight (8) years ago, a doctor from Seattle, Washington diagnosed with prostate cancer nine (9) years ago. Each was advised by their personal doctors that their tumors were beyond the reach of conventional medicine.

Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002 Feb;29(1):82-96.

University Department of Medicine, University of Western Australia, Verdun St Nedlands, Australia.

Although malignant mesothelioma is not a classically immunogenic cancer, there is abundant evidence for immune recognition. The relative ease of obtaining tumor tissue makes mesothelioma ideal for studying surrogate biomarkers such as lymphocytic infiltration or expression of transduced genes. There is evidence that malignant mesothelioma patients as well as asbestos-exposed persons without mesothelioma have impaired immune responsiveness. Substantial progress has been made in animal models using several biological and immunological techniques, but clinical application has been problematic. Systems studied have included lysis by interleukin-2 (IL-2)-activated lymphokine-activated killer (LAK) cells, tumor necrosis factor-alpha (TNF-alpha), a p16-expressing adenovirus vector, suicide gene therapy using the herpes simplex virus-tyrosine kinase (HSV-tk) followed by ganciclovir, and immunomodulatory gene therapy with IL-2, IL-4, interferon-gamma (IFN-gamma), IFN-alpha, TNF-alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-6, and IL-1beta transfected into tumors. Vaccinia virus has been studied as a vector for cytokine gene transfer. Suicide gene therapy has been combined with a tumor vaccine. The University of Western Australia is initiating a pilot study of autologous vaccination in malignant mesothelioma. Novel agents under study include the angiogenesis inhibitors SU5416, bevacizumab, and thalidomide. ZD1839, an orally administered, highly selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase, is being tested in a phase II trial. Since platelet-derived growth factor (PDGF) is thought to be an autocrine growth factor for mesothelioma STI-571 (Gleevec; Novartis, Basel, Switzerland), a highly selective inhibitor of the PDGF receptor tyrosine kinase, is being tested in a phase II trial. The development of more active cytotoxic combinations in this disease should facilitate further studies of chemoimmunotherapy. It seems likely that no single treatment modality will be effective by itself. Copyright 2002 by W.B. Saunders Company.

Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity. Cancer Res. 2001 Aug 15;61(16):6201-12.

Odaka M, Sterman DH, Wiewrodt R, Zhang Y, Kiefer M, Amin KM, Gao GP, Wilson JM, Barsoum J, Kaiser LR, Albelda SM. Thoracic Oncology Research Laboratory, Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania 19104, USA.

Malignant mesothelioma remains an incurable disease for which immune-modulatory therapies, such as exogenous cytokines, have shown some promise. One such cytokine, IFN-beta, has potent antiproliferative and immunostimulatory activity in vitro, but its in vivo use has been limited by toxicity. We thus conducted studies evaluating intracavitary delivery of a replication-deficient adenoviral (Ad) vector encoding for the murine IFN-beta gene (Ad.muIFN-beta) in mouse models of malignant mesothelioma. In contrast to multiple injections of recombinant protein, a single i.p. injection of Ad.muIFN-beta into animals with established tumors elicited remarkable antitumor activity leading to long-term survival in >90% of animals bearing either AB12 or AC29 i.p. mesotheliomas. A control adenovirus vector had minimal antitumor effect in vivo. Significant therapeutic effects were also seen in animals treated with large tumor burdens. Importantly, treatment of i.p. tumor also led to reduction of growth in tumors established at a distant site (flank). A number of experiments suggested that these effects were attributable to an acquired CD8(+) T-cell-mediated response including: (a) the induction of long-lasting antitumor immunity; (b) loss of efficacy of Ad.muIFN-beta in tumor-bearing, immune-deficient (SCID, SCID/beige) mice; (c) detection of high levels of specific antitumor cytolytic activity from unstimulated splenocytes harvested from Ad.muIFN-beta-treated animals that was abolished by CD8(+) T-cell depletion; and (d) abrogation of antitumor effects of Ad.muIFN-beta in tumor-bearing CD8(+) T-cell-depleted animals. These data show that intracavitary IFN-beta gene therapy using an adenoviral vector provides strong CD8(+) T-cell-mediated antitumor effects in murine models of mesothelioma and suggest that this may be a promising strategy for the treatment of localized tumors such as mesothelioma or ovarian cancer in humans.

Source